Avexa Of Australia Reports Good Results With HIV Drug
This article was originally published in PharmAsia News
Australian drug maker Avexa reports positive results from a Phase II study of its apricitabine HIV drug to treat patients unresponsive to GlaxoSmithKline's Epivir (lamivudine). Avexa CEO Julian Chick said the study showed the firm's drug to be at least as good as the safest HIV drug on the market. The study reported the drug reduced the AIDS-causing virus to insignificant levels in 89 percent of patients. Avexa seeks to license marketing rights to a larger partner so it can complete the studies this year. (Click here for more
You may also be interested in...
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
EU Scientific Committee Affirms Safety Of Anti-Dandruff Zinc Pyrithione Under Threat Of Cosmetic Ban
The Scientific Committee for Consumer Safety upholds that zinc pyrithione is safe for use in rinse-off anti-dandruff hair products at levels up to 1%. In recent years, the cosmetics industry has pushed for a 2% ceiling on ZPT content in that capacity – with considerable inroads made. Where that proposal now stands vis-à-vis the ingredient’s pending CMR 1B classification and shifting political sands is uncertain.